"The German Government will be providing the Access to Covid-19 Tools Accelerator (ACT-Accelerator) with an additional 1.5 billion euro of funding in 2021. Most of this sum will go to the vaccine platform COVAX, which is procuring and financing vaccines for developing countries," the statement reads.
This money willl go to the vaccine platform COVAX, while some will be used for diagnostic tools and medication to treat Covid-19. The funding will enable COVAX to procure more vaccines, distribute the doses and support progress in vaccine research looking at virus mutations.
The ACT-Accelerator has already coordinated the procurement of two billion doses as well as liability and approval issues for 190 countries, halved the cost of rapid tests for developing countries and procured 2.9 million doses of the drug dexamethasone for treating Covid-19 patients in developing countries.
Germany joined COVAX via the EU and was already the third-largest donor to the ACT-Accelerator, with an initial contribution of 600 million euro.
The EU itself is providing 500 million euro in start-up funding for COVAX and is sharing its technical expertise. Germany will also provide a substantial contribution to support developing countries. In addition to this and other support, Germany has made available 450 million euro for humanitarian assistance in the context of Covid-19 and is working in all international bodies to promote fair, transparent and affordable access to Covid-19 vaccines, medicines and diagnostics around the globe.
As we reported earlier, Germany has allocated 21 million euros (25.3 million dollars) to implement the Action Plan Civil Society Belarus initiative aimed at providing support to the Belarusian opposition.